



July 1, 2024

PeptiDream Inc  
<https://www.peptidream.com>  
 (Securities Code: 4587 TSE Prime Market)

## Dr. Masato Murakami Appointed as President and Representative Director of PDRadiopharma

KANAGAWA, JAPAN – July 1, 2024 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced that PDRadiopharma Inc., (“PDRadiopharma”), a wholly-owned subsidiary of PeptiDream, has appointed Dr. Masato Murakami as its Representative Director and President, effective July 1, 2024. Dr. Murakami joined PeptiDream in January of 2022 as Chief Medical Officer (“CMO”), and subsequently joined the board of PDRadiopharma as a non-executive director in November of 2023. In addition to his new role as Representative Director and President of PDRadiopharma, Dr. Murakami will continue to serve in his role as PeptiDream’s CMO.

Name	Previous Roles	New Roles (July 1, 2024)
Masato Murakami M.D., Ph.D., MBA	<b>PeptiDream Inc.</b> Chief Medical Officer (CMO)  <b>PDRadiopharma Inc.</b> Non-executive Director	<b>PeptiDream Inc.</b> Chief Medical Officer (CMO)  <b>PDRadiopharma Inc.</b> President and Representative Director Division Director, Research & Development Div.

*“The arrival of targeted radiotherapeutics and radiodiagnostics are revolutionizing the radiopharmaceutical field and transforming how we diagnose and treat cancer.”* said **Masato Murakami, CMO of PeptiDream.** *“In my new role as President, I look forward to working with everyone at PDRadiopharma to maximize the synergies with PeptiDream and continue to expand our portfolio of targeted radiotherapeutics and radiodiagnostics and deliver on our aim of being the leading radiopharmaceutical company in Japan and getting these life-changing medicines to patients as soon as possible.”*

*“We are highly focused on expanding and advancing a broad pipeline of targeted radiotherapeutic and radiodiagnostic programs, both internal and partnered, into the clinic and PDRadiopharma is playing an instrumental role in these efforts. I couldn’t be more proud of the PeptiDream and PDRadiopharma teams, and I am confident that Dr. Murakami is the right person to lead PDRadiopharma and help us continue to integrate the two organizations into the leading radiopharmaceutical company in Japan.”* said Patrick C. Reid, **CEO of PeptiDream.**

**About PeptiDream Inc.**

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our PeptiDream, science and pipeline, please visit [www.peptidream.com](http://www.peptidream.com).

### **About PDRadiopharma**

PDRadiopharma, since 2022 a wholly-owned subsidiary of PeptiDream, was founded in 1968 and has a rich history as one of the leading radiopharmaceutical companies in Japan. With more than 500 employees spanning development, manufacturing, regulatory, and sales, PDRadiopharma currently markets 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit [www.pdradiopharma.com](http://www.pdradiopharma.com).

### **Inquiries:**

#### **PeptiDream Inc.**

Contact: Yuko Okimoto, IR & Public Affairs

Email: [info@peptidream.com](mailto:info@peptidream.com)